Literature DB >> 1988240

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.

W Kalow1, B K Tang.   

Abstract

It has been realized recently that the primary metabolism of caffeine in humans is catalyzed by P-450IA2 and that the rate of caffeine metabolism can be estimated from a metabolic ratio in a single urine sample. A population of 178 students including 19 smokers were subjected to this caffeine test to establish their P-450IA2 index. Both stated numbers of cigarettes smoked per day and urinary cotinine levels as a confirmatory measure correlated significantly with enzyme activity showing dose-effect relationships (r = 0.62 and 0.89, respectively). Nevertheless, more nonsmokers than smokers had the highest enzyme indexes, suggesting that dietary elements or other factors may determine P-450IA2 activities in populations. Because P-450IA2 is a monooxygenase that may be confined to the liver, caffeine reveals directly the Ah-receptor-dependent enzyme induction only in the liver, but it may also be a signal of induction elsewhere.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988240     DOI: 10.1038/clpt.1991.8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  47 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Authors:  Natasa Djordjevic; Roza Ghotbi; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

4.  CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

5.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

6.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

7.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

8.  Xanthine oxidase activity is influenced by environmental factors in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

9.  Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.

Authors:  Natasa Djordjevic; Roza Ghotbi; Leif Bertilsson; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2007-12-22       Impact factor: 2.953

10.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.